Skip to main content
Premium Trial:

Request an Annual Quote

Belgium s Galapagos to Build Gene Library for Pharmacia

NEW YORK, Nov. 14 – Belgian functional genomics company Galapagos Genomics said Wednesday that it had agreed to build a gene library for Pharmacia designed to help the pharmaceutical company to identify and validate drug targets for a range of diseases.

Galapagos has developed the PhenoSelect expression platform, which uses arrayed adenoviruses containing human genes to identify and validate targets.

"We are proud of the confidence that Pharmacia has expressed in our technology platform, and we feel strongly that this collaboration will result in an expedited identification and validation of novel drug targets for Pharmacia,” Onno van de Stolpe, Galapagos’ CEO, said in a statement. 

Financial terms of the deal were not disclosed. Pharmacia of Peapack, NJ, was not immediately available to comment on the deal.

Galapagos’ other partners include Bayer, Vertex Pharmaceuticals, Incyte, Procter&Gamble, and the Netherlands Cancer Institute.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.